Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M21,702Revenue (TTM) $M1,292Net Margin (%)-30.9Altman Z-Score5.4
Enterprise Value $M21,643EPS (TTM) $-1.6Operating Margin %-23.9Piotroski F-Score4
P/E(ttm)--Beneish M-Score-0.8Pre-tax Margin (%)-30.2Higher ROA y-yY
Price/Book22.610-y EBITDA Growth Rate %--Quick Ratio2.4Cash flow > EarningsY
Price/Sales16.55-y EBITDA Growth Rate %--Current Ratio2.5Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-16.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-42.6Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M247ROIC % (ttm)-47.7Gross Margin Increase y-yN

Gurus Latest Trades with VRTX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VRTXVanguard Health Care Fund 2016-03-31 Add0.5%$78.4 - $125.83
($91.01)
$ 87.74-4%Add 28.91%12,668,241
VRTXLeucadia National 2016-03-31 Buy 0.04%$78.4 - $125.83
($91.01)
$ 87.74-4%New holding3,300
VRTXJohn Paulson 2016-03-31 Add0.01%$78.4 - $125.83
($91.01)
$ 87.74-4%Add 32.54%61,500
VRTXJoel Greenblatt 2016-03-31 Reduce-0.01%$78.4 - $125.83
($91.01)
$ 87.74-4%Reduce -57.21%5,046
VRTXKen Fisher 2016-03-31 Reduce$78.4 - $125.83
($91.01)
$ 87.74-4%Reduce -7.00%5,155
VRTXVanguard Health Care Fund 2015-12-31 Add0.1%$109.03 - $133.26
($121.16)
$ 87.74-28%Add 4.34%9,827,411
VRTXJohn Paulson 2015-12-31 Buy 0.04%$109.03 - $133.26
($121.16)
$ 87.74-28%New holding46,400
VRTXJoel Greenblatt 2015-12-31 Buy 0.02%$109.03 - $133.26
($121.16)
$ 87.74-28%New holding11,793
VRTXKen Fisher 2015-12-31 Add$109.03 - $133.26
($120.93)
$ 87.74-27%Add 12.48%5,543
VRTXVanguard Health Care Fund 2015-09-30 Reduce-0.03%$98.5 - $141.48
($128.47)
$ 87.74-32%Reduce -1.21%9,418,411
VRTXKen Fisher 2015-09-30 Add$98.5 - $141.48
($128.47)
$ 87.74-32%Add 12.56%4,928
VRTXGeorge Soros 2015-06-30 Sold Out -0.07%$116.43 - $135.82
($125.88)
$ 87.74-30%Sold Out0
VRTXKen Fisher 2015-06-30 Reduce$116.43 - $135.82
($125.88)
$ 87.74-30%Reduce -0.18%4,378
VRTXVanguard Health Care Fund 2015-03-31 Reduce-0.08%$107.88 - $134.25
($119.81)
$ 87.74-27%Reduce -2.80%9,533,911
VRTXGeorge Soros 2015-03-31 Buy 0.07%$107.88 - $134.25
($119.81)
$ 87.74-27%New holding56,912
VRTXKen Fisher 2015-03-31 Add$107.88 - $134.25
($119.81)
$ 87.74-27%Add 0.18%4,386
VRTXVanguard Health Care Fund 2014-12-31 Reduce-0.58%$101.1 - $120.78
($112.61)
$ 87.74-22%Reduce -16.93%9,808,860
VRTXKen Fisher 2014-09-30 Reduce$84.74 - $113.9
($94.97)
$ 87.74-8%Reduce -31.99%4,593
VRTXVanguard Health Care Fund 2014-06-30 Add0.04%$62.44 - $94.68
($70.13)
$ 87.7425%Add 1.54%11,807,500
VRTXGeorge Soros 2014-06-30 Sold Out -0.01%$62.44 - $93.77
($69.73)
$ 87.7426%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VRTX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


VRTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BOGER JOSHUA SDirector 2016-06-29Sell5,130$84.821.41view
BOGER JOSHUA SDirector 2016-06-22Sell5,130$86.61-0.68view
BOGER JOSHUA SDirector 2016-06-15Sell5,130$91.18-5.66view
BOGER JOSHUA SDirector 2016-06-08Sell5,130$94.95-9.4view
BOGER JOSHUA SDirector 2016-06-01Sell5,130$93.65-8.15view
BOGER JOSHUA SDirector 2016-05-25Sell5,130$89.09-3.45view
BOGER JOSHUA SDirector 2016-05-18Sell5,130$81.185.96view
Sachdev AmitEVP, Policy, Access & Value 2016-05-16Sell117$81.675.33view
Silva Paul MSVP & Corp Controller 2016-05-16Sell202$82.064.83view
SMITH IAN FEVP & CFO 2016-05-16Sell202$82.064.83view

Quarterly/Annual Reports about VRTX:

    News about VRTX:

    Articles On GuruFocus.com
    Vanguard Health Care Fund Ups Stake in High-Conviction Stocks May 10 2016 
    Vanguard Boosts Stake in Incyte in 1st Quarter May 02 2016 
    Kyle Bass Sells Stakes in 11 Health Care Companies Mar 01 2016 
    Lee Ainslie Adds 90 New Stocks to His Portfolio Within the First Quarter May 20 2015 
    Analysts Confident That Vertex Pharmaceuticals' CF Drug Will Receive FDA Approval May 13 2015 
    Fate Of Cystic Fibrosis Drug By Vertex Is Now Dependent On FDA Approval May 13 2015 
    J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
    William Blair’s Top BioPharmaceutical Stock Picks for Q1 2015 Dec 23 2014 
    Weekly CFO Sells Highlight: Texas Instruments Inc, Royal Caribbean Cruises Ltd, Vertex Pharmaceutica Nov 09 2014 
    Weekly CFO Sells Highllight: Facebook Inc, Vertex Pharmaceuticals Inc, Nike Inc. Oct 05 2014 

    More From Other Websites
    5 Top Biotechs Where Future Multi-Billion Dollar Drug Pipelines are Valued Almost at Zero Jun 28 2016
    Biotechs: After Brexit, Buy the Stocks and Get the Pipelines For Free Jun 28 2016
    Zacks.com featured highlights: Antero Resources, ZELTIQ Aesthetics, Vertex Pharmaceuticals, ViaSat... Jun 28 2016
    Brexit vote costs these 10 Mass. firms $18B in market value today Jun 27 2016
    How Does Brexit Impact Healthcare Stocks? Jun 27 2016
    Dump These 5 Toxic Stocks to Avoid Portfolio Bleeding Jun 27 2016
    How Does Brexit Affect Biotech Stocks? Wall Street Weighs In Jun 24 2016
    Vertex Pharmaceuticals, Inc. – Value Analysis (NASDAQ:VRTX) : June 21, 2016 Jun 21 2016
    Vertex Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VRTX-US : June... Jun 20 2016
    VERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K, Change in Directors or Principal Officers Jun 15 2016
    Downside Ahead For Biotech Stocks? Jun 10 2016
    Vertex Announces Presentations of Data for KALYDECO® (ivacaftor) and ORKAMBI®... Jun 10 2016
    Vertex Announces Presentations of Data for KALYDECO® (ivacaftor) and ORKAMBI®... Jun 10 2016
    5 Toxic Stocks to Discard from Your Portfolio Right Now Jun 09 2016
    ​A look inside the fantastic pill-making machine at Vertex Pharmaceuticals Jun 07 2016
    Biogen: 'Major Upside Opportunity Gone' Jun 07 2016
    Biotech: Is the Rally Real? Jun 02 2016
    Vertex Receives FDA Nod for Priority Review of Orkambi Jun 01 2016
    Vertex (VRTX) Orkambi sNDA Accepted with Priority Review Jun 01 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)